NZ512267A - Ionic silver complex - Google Patents
Ionic silver complexInfo
- Publication number
- NZ512267A NZ512267A NZ512267A NZ51226799A NZ512267A NZ 512267 A NZ512267 A NZ 512267A NZ 512267 A NZ512267 A NZ 512267A NZ 51226799 A NZ51226799 A NZ 51226799A NZ 512267 A NZ512267 A NZ 512267A
- Authority
- NZ
- New Zealand
- Prior art keywords
- solution
- silver
- complexing agent
- acid
- citrate
- Prior art date
Links
- 229910052709 silver Inorganic materials 0.000 title claims abstract description 153
- 239000004332 silver Substances 0.000 title claims abstract description 153
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title claims abstract description 115
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000008139 complexing agent Substances 0.000 claims abstract description 32
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 5
- 150000001261 hydroxy acids Chemical class 0.000 claims abstract description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 208000025865 Ulcer Diseases 0.000 claims abstract description 4
- 238000011109 contamination Methods 0.000 claims abstract description 4
- 239000011591 potassium Substances 0.000 claims abstract description 4
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 4
- 231100000397 ulcer Toxicity 0.000 claims abstract description 4
- 229940071575 silver citrate Drugs 0.000 claims abstract 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000011575 calcium Substances 0.000 claims abstract 3
- 229910052791 calcium Inorganic materials 0.000 claims abstract 3
- -1 silver ions Chemical class 0.000 claims description 48
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 10
- 230000000845 anti-microbial effect Effects 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 9
- 235000015165 citric acid Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 244000052616 bacterial pathogen Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010046914 Vaginal infection Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000001172 regenerating effect Effects 0.000 claims description 3
- 150000003335 secondary amines Chemical class 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 206010003399 Arthropod bite Diseases 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 201000006082 Chickenpox Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 208000001860 Eye Infections Diseases 0.000 claims description 2
- 206010018785 Gingival infections Diseases 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 206010046980 Varicella Diseases 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000000840 anti-viral effect Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960005261 aspartic acid Drugs 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 208000011323 eye infectious disease Diseases 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- 235000014304 histidine Nutrition 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229960003136 leucine Drugs 0.000 claims description 2
- 235000018977 lysine Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 229960005190 phenylalanine Drugs 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- 235000008521 threonine Nutrition 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- 235000002374 tyrosine Nutrition 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 229960004295 valine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010068319 Oropharyngeal pain Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229940059082 douche Drugs 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 210000004357 third molar Anatomy 0.000 claims 1
- 229960004799 tryptophan Drugs 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 40
- 150000002500 ions Chemical class 0.000 description 14
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 231100000252 nontoxic Toxicity 0.000 description 12
- 230000003000 nontoxic effect Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 230000037406 food intake Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229910001923 silver oxide Inorganic materials 0.000 description 7
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 6
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000001508 potassium citrate Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960002635 potassium citrate Drugs 0.000 description 4
- 235000011082 potassium citrates Nutrition 0.000 description 4
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 235000012206 bottled water Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003221 ear drop Substances 0.000 description 2
- 229940047652 ear drops Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229910001961 silver nitrate Inorganic materials 0.000 description 2
- 208000035985 Body Odor Diseases 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229940050931 potassium citrate monohydrate Drugs 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000936 topical exposure Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015870 tripotassium citrate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/06—Chelate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/13—Burn treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Colloid Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10771098P | 1998-11-09 | 1998-11-09 | |
| PCT/US1999/026223 WO2000027390A1 (en) | 1998-11-09 | 1999-11-05 | Ionic silver complex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ512267A true NZ512267A (en) | 2003-11-28 |
Family
ID=22318046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ512267A NZ512267A (en) | 1998-11-09 | 1999-11-05 | Ionic silver complex |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20020025344A1 (OSRAM) |
| EP (1) | EP1128824A1 (OSRAM) |
| JP (2) | JP2002529411A (OSRAM) |
| AU (1) | AU776212B2 (OSRAM) |
| BR (1) | BR9915174A (OSRAM) |
| NZ (1) | NZ512267A (OSRAM) |
| WO (1) | WO2000027390A1 (OSRAM) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1293805C (zh) * | 1997-10-10 | 2007-01-10 | 纯生物科学公司 | 消毒剂及其制造方法 |
| WO2000027390A1 (en) * | 1998-11-09 | 2000-05-18 | Ira Jay Newman | Ionic silver complex |
| US7261905B2 (en) * | 1999-04-07 | 2007-08-28 | Pure Bioscience | Disinfectant and method of making |
| US6242009B1 (en) | 1999-04-20 | 2001-06-05 | Kareem I. Batarseh | Microbicidal formulations and methods to control microorganisms |
| US7137968B1 (en) * | 2000-03-13 | 2006-11-21 | Nucryst Pharmaceuticals Corp. | Transcutaneous medical device dressings and method of use |
| US6890953B2 (en) | 2000-04-06 | 2005-05-10 | Innovative Medical Services | Process for treating water |
| US6719987B2 (en) | 2000-04-17 | 2004-04-13 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
| US20030180379A1 (en) | 2000-07-27 | 2003-09-25 | Burrell Robert E. | Solutions and aerosols of metal-containing compounds |
| ATE282420T1 (de) | 2000-07-27 | 2004-12-15 | Nucryst Pharm Corp | Verwendung von edelmetallen zur herstellung eines arzneitmittels zur behandlung von hyperproliferativen hautstörungen und krankheiten |
| US7255881B2 (en) * | 2000-07-27 | 2007-08-14 | Nucryst Pharmaceuticals Corp. | Metal-containing materials |
| US20040191329A1 (en) * | 2000-07-27 | 2004-09-30 | Burrell Robert E. | Compositions and methods of metal-containing materials |
| US20030185901A1 (en) | 2000-07-27 | 2003-10-02 | Burrell Robert E. | Methods of treating conditions with a metal-containing material |
| US7001617B2 (en) | 2001-04-23 | 2006-02-21 | Nueryst Pharmaceuticals Corp. | Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals |
| US20030206966A1 (en) * | 2000-07-27 | 2003-11-06 | Burrell Robert E. | Methods of inducing apoptosis and modulating metalloproteinases |
| US7008647B2 (en) | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
| US6989157B2 (en) | 2000-07-27 | 2006-01-24 | Nucryst Pharmaceuticals Corp. | Dry powders of metal-containing compounds |
| US7427416B2 (en) | 2000-07-27 | 2008-09-23 | Nucryst Pharmaceuticals Corp. | Methods of treating conditions using metal-containing materials |
| DE10043151A1 (de) * | 2000-08-31 | 2002-03-28 | Peter Steinruecke | Knochenzement mit antimikrobieller Wirksamkeit |
| US6630172B2 (en) | 2001-01-22 | 2003-10-07 | Kareem I. Batarseh | Microbicidal composition containing potassium sodium tartrate |
| US6723350B2 (en) * | 2001-04-23 | 2004-04-20 | Nucryst Pharmaceuticals Corp. | Lubricious coatings for substrates |
| US7201925B2 (en) | 2002-04-23 | 2007-04-10 | Nueryst Pharmaceuticals Corp. | Treatment of ungual and subungual diseases |
| US20040044073A1 (en) * | 2002-08-31 | 2004-03-04 | Innovative Medical Services | Composition and process for treating acne |
| JP2006509738A (ja) * | 2002-10-22 | 2006-03-23 | ニュクリスト ファーマシューティカルズ コーポレーション | 予防的治療法 |
| US7435438B1 (en) | 2003-05-16 | 2008-10-14 | Pure Bioscience | Disinfectant and method of use |
| DK200301128A (da) * | 2003-08-05 | 2005-02-06 | Thomsen Joern Oddershede | Tilskudspræparat |
| WO2005041861A2 (en) * | 2003-08-28 | 2005-05-12 | Pure Bioscience | Anhydrous silver dihydrogen citrate compositions |
| US20050058673A1 (en) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
| SE528045C2 (sv) * | 2004-02-23 | 2006-08-15 | Polygiene Ab | Användning av en plastkomposition för att förse en yta med antivirusaktivitet |
| JP5586816B2 (ja) | 2004-03-15 | 2014-09-10 | 大正製薬株式会社 | 亜鉛化合物配合組成物 |
| CA2565556A1 (en) * | 2004-05-03 | 2005-12-08 | Neosil, Inc. | Polycationic antimicrobial therapeutic |
| US20060051384A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
| US20060051430A1 (en) * | 2004-09-07 | 2006-03-09 | Arata Andrew B | Silver dihydrogen citrate compositions |
| US8198326B2 (en) * | 2004-09-07 | 2012-06-12 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
| US20060115440A1 (en) * | 2004-09-07 | 2006-06-01 | Arata Andrew B | Silver dihydrogen citrate compositions |
| US9028852B2 (en) * | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
| US8048870B2 (en) * | 2005-01-11 | 2011-11-01 | Batarseh Kareem I | Apoptosis-inducing antineoplastic silver (I) coordination complexes |
| US8476319B2 (en) * | 2005-03-10 | 2013-07-02 | 3M Innovative Properties Company | Methods of treating ear infections |
| TW200716200A (en) * | 2005-03-10 | 2007-05-01 | 3M Innovative Properties Co | Methods of reducing microbial contamination |
| ATE511838T1 (de) * | 2005-03-10 | 2011-06-15 | 3M Innovative Properties Co | Antimikrobielle zusammensetzungen mit hydroxycarboxylsäureestern |
| US20060216322A1 (en) * | 2005-03-25 | 2006-09-28 | Kenko Corporation | Feed composition and method for breeding animals |
| US20060263444A1 (en) * | 2005-05-19 | 2006-11-23 | Xintian Ming | Antimicrobial composition |
| US20090074881A1 (en) * | 2006-05-02 | 2009-03-19 | Bioneutral Laboratories Corporation Usa | Antimicrobial cidality formulations with residual efficacy, uses thereof, and the preparation thereof |
| US20080014278A1 (en) * | 2006-06-30 | 2008-01-17 | Nucryst Pharmaceuticals | Metal-containing formulations and methods of use |
| EP1938690B1 (de) * | 2006-12-22 | 2013-10-23 | Preentec AG | Sterilisierung und Konservierung von Fluiden |
| US7520923B2 (en) * | 2007-03-22 | 2009-04-21 | Mvp Textiles & Apparel, Inc. | Antimicrobial filtration article |
| US9393261B2 (en) * | 2011-07-22 | 2016-07-19 | Body Glide LLC | Antimicrobial anti-chafing chelated silver oxide compound |
| US9132296B2 (en) | 2007-05-17 | 2015-09-15 | Ag Essence | Antimicrobial solution and methods of making and using the same |
| EP2497363A1 (en) * | 2007-05-18 | 2012-09-12 | Sciessent, LLC | Bioactive agrichemical compositions and use thereof |
| WO2009085651A1 (en) * | 2007-12-20 | 2009-07-09 | Nucryst Pharmaceuticals Corp. | Metal carbonate particles for use in medicine and methods of making thereof |
| CN102118974A (zh) * | 2008-06-06 | 2011-07-06 | 纯生物科学 | 柠檬酸二氢银的农业应用 |
| DE102008031927B4 (de) | 2008-07-08 | 2017-09-14 | Beiersdorf Ag | Kosmetische Zubereitungen mit passiviertem Silber |
| US8399028B2 (en) * | 2008-08-14 | 2013-03-19 | Exciton Technologies Inc. | Antimicrobial silver solutions |
| US8535729B2 (en) * | 2008-12-05 | 2013-09-17 | The Clorox Company | Natural silver disinfectant compositions |
| US9295254B2 (en) | 2011-12-08 | 2016-03-29 | Sciessent Llc | Nematicides |
| JP6001906B2 (ja) * | 2012-04-04 | 2016-10-05 | 株式会社Ｐｏｗｅｒｆｕｌ Ｔｒａｄｅ Ｌｉｍｉｔｅｄ Ｊａｐａｎ | 瓦礫用の静菌殺菌消臭組成物の製造方法及び瓦礫用の静菌殺菌消臭組成物 |
| US11547116B2 (en) * | 2012-12-12 | 2023-01-10 | William Wingfield | Metal oxide compounds and infusion into polymer compounds |
| US11618696B2 (en) | 2013-08-15 | 2023-04-04 | Applied Silver, Inc. | Antimicrobial batch dilution system |
| US10640403B2 (en) | 2013-08-15 | 2020-05-05 | Applied Silver, Inc. | Antimicrobial batch dilution system |
| US9689106B2 (en) | 2013-12-06 | 2017-06-27 | Applied Silver, Inc. | Antimicrobial fabric application system |
| JP6622218B2 (ja) * | 2014-01-27 | 2019-12-18 | エイダンス スキンケア アンド トピカル ソリューションズ エルエルシー | 局所抗生物質製剤 |
| EP3337831B1 (en) | 2015-08-21 | 2024-02-28 | G&P Holding, Inc. | Silver and copper itaconates and poly itaconates |
| US20170050870A1 (en) | 2015-08-21 | 2017-02-23 | Applied Silver, Inc. | Systems And Processes For Treating Textiles With An Antimicrobial Agent |
| CN108882713B (zh) * | 2015-10-21 | 2021-07-20 | 荷兰联合利华有限公司 | 抗微生物组合物 |
| WO2017197260A1 (en) | 2016-05-12 | 2017-11-16 | Applied Silver, Inc. | Articles and methods for dispensing metal ions into laundry systems |
| WO2018081774A1 (en) | 2016-10-31 | 2018-05-03 | Applied Silver, Inc. | Dispensing of metal ions into batch laundry washers and dryers |
| US20200123700A1 (en) | 2017-03-01 | 2020-04-23 | Applied Silver, Inc. | Systems and processes for treating textiles with an antimicrobial agent |
| EA029076B1 (ru) * | 2017-03-22 | 2018-02-28 | Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) | Антимикробное средство |
| KR102123206B1 (ko) * | 2020-02-19 | 2020-06-16 | 곽병상 | 은 화합물과 착화제를 포함하는 항균 조성물 |
| CN111205312B (zh) * | 2020-03-31 | 2021-03-16 | 榫卯科技服务(温州)有限公司 | 一种抗菌稀土配合物材料以及制备方法 |
| KR102223638B1 (ko) * | 2020-07-28 | 2021-03-04 | 곽병상 | 은 화합물과 착화제를 함유하는 항균 조성물 및 삼칠근 추출물을 유효성분으로 포함하는 혈중 전립선 특이항원 안정화제 |
| WO2022031537A1 (en) * | 2020-08-03 | 2022-02-10 | Reed Frank Joseph | Compositions for prevention and treatment of rsv and coronavirus infection |
| WO2023019026A1 (en) * | 2021-08-13 | 2023-02-16 | Onyx Lotus, Llc | Light stable liquid disinfectant compositions |
| CN114766520A (zh) * | 2022-05-20 | 2022-07-22 | 千藤（南京）环保科技有限公司 | 一种柠檬酸三银组合物、制备方法及用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE400040A (OSRAM) * | ||||
| NL147015B (nl) | 1971-02-16 | 1975-09-15 | Basf Ag | Werkwijze ter bereiding van een middel voor het in frisse staat houden van snijbloemen. |
| US3826639A (en) * | 1971-02-16 | 1974-07-30 | Basf Ag | Agent for keeping cut flowers fresh |
| DE2260566A1 (de) | 1972-12-11 | 1974-06-12 | Christoffers Maschinenfab Gmbh | Draht-nassziehmaschine (schottwand) |
| US4055655A (en) | 1975-07-21 | 1977-10-25 | National Research Laboratories | Complexes of heavy metal ions and polyfunctional organic ligands used as antimicrobial agents |
| FR2399847A1 (fr) | 1977-08-11 | 1979-03-09 | Nat Res Lab | Agents antimicrobiens et leur application |
| JPS5437824A (en) * | 1977-08-30 | 1979-03-20 | Nat Risaachi Lab | Bacteriocide comprising metal complex compound |
| CA1218600A (en) * | 1982-12-06 | 1987-03-03 | Gerald L. Maurer | Methods and compositions for treating inflammation or arthritis |
| JPS59126492A (ja) * | 1982-12-24 | 1984-07-21 | Fujitsu Ltd | 液晶組成物 |
| JPH0622540B2 (ja) * | 1985-12-18 | 1994-03-30 | 株式会社祥光化学研究所 | 消臭抗菌能を有する構造物 |
| CH673225A5 (OSRAM) * | 1986-04-22 | 1990-02-28 | Sanosil Ag | |
| JPH02111709A (ja) * | 1988-10-20 | 1990-04-24 | Agency Of Ind Science & Technol | 粉末状抗菌抗かび剤及びその製法 |
| US5032612A (en) * | 1990-05-25 | 1991-07-16 | Smolko Milan J | Non-smoking aid |
| DE4123292C2 (de) | 1991-07-13 | 1996-01-25 | Hungerbach Chemotechnik Gmbh | Mundhygienemittel und Verwendung einer mit einem Silberkolloid stabilisierten Wasserstoffperoxid-Lösung in Mundhygienemitteln |
| EP0724449A1 (en) * | 1991-09-20 | 1996-08-07 | Similasan Corporation | Preservative for pharmaceutical products |
| US5322520A (en) | 1992-11-12 | 1994-06-21 | Implemed, Inc. | Iontophoretic structure for medical devices |
| JP3595352B2 (ja) * | 1993-02-01 | 2004-12-02 | 株式会社サンギ | 抗腫瘍剤及び抗菌剤 |
| GB9309387D0 (en) * | 1993-05-06 | 1993-06-16 | Wellcome Found | Nitric oxide scavengers |
| EP0727427A4 (en) | 1993-11-05 | 1997-10-15 | Meiji Milk Prod Co Ltd | ANTIBACTERIAL, ANTI-FUNGI AND ANTIVIRES |
| US5961843A (en) | 1994-10-05 | 1999-10-05 | Toto Ltd. | Antimicrobial solid material, process for producing the same, and method of utilizing the same |
| US5824292A (en) | 1995-04-12 | 1998-10-20 | Quest International B.V. | Oral care compositions |
| JP3449123B2 (ja) * | 1996-07-22 | 2003-09-22 | 旭硝子株式会社 | 低抵抗膜又は低屈折率膜形成用塗布液、及び、低抵抗膜又は低反射低屈折率膜の製造方法 |
| US5688981A (en) * | 1996-11-21 | 1997-11-18 | Hampshire Chemical Corp. | Ethylenediaminetriacetic acid and N-acyl ethylenediaminetriacetic acid silver chelating agents and surfactants |
| US5785972A (en) | 1997-01-10 | 1998-07-28 | Tyler; Kathleen A. | Colloidal silver, honey, and helichrysum oil antiseptic composition and method of application |
| US5932251A (en) | 1997-04-23 | 1999-08-03 | Kirkpatrick; Carole M. | Hair growth promoter and method of using same |
| NL1005965C2 (nl) * | 1997-05-05 | 1998-11-13 | Tevan Chemie B V | Samenstelling met desinfecterende werking. |
| CN1293805C (zh) | 1997-10-10 | 2007-01-10 | 纯生物科学公司 | 消毒剂及其制造方法 |
| JP2000016905A (ja) * | 1998-07-01 | 2000-01-18 | Tokuriki Kagaku Kenkyusho:Kk | 抗菌抗かび剤および抗菌抗かび材料 |
| WO2000027390A1 (en) * | 1998-11-09 | 2000-05-18 | Ira Jay Newman | Ionic silver complex |
| EP1036511A3 (de) | 1999-03-15 | 2001-08-29 | Ralf M. Kern | Verfahren zur Haltbarmachung und Mittel zu dessen Durchführung |
-
1999
- 1999-11-05 WO PCT/US1999/026223 patent/WO2000027390A1/en not_active Ceased
- 1999-11-05 BR BR9915174-0A patent/BR9915174A/pt not_active Application Discontinuation
- 1999-11-05 AU AU14701/00A patent/AU776212B2/en not_active Ceased
- 1999-11-05 JP JP2000580619A patent/JP2002529411A/ja active Pending
- 1999-11-05 EP EP99971711A patent/EP1128824A1/en not_active Ceased
- 1999-11-05 NZ NZ512267A patent/NZ512267A/en unknown
-
2001
- 2001-02-28 US US09/796,242 patent/US20020025344A1/en not_active Abandoned
-
2002
- 2002-06-18 US US10/175,260 patent/US20020150628A1/en not_active Abandoned
-
2003
- 2003-03-07 US US10/383,345 patent/US6838095B2/en not_active Expired - Lifetime
-
2005
- 2005-01-04 US US11/028,840 patent/US20050118281A1/en not_active Abandoned
-
2011
- 2011-12-16 JP JP2011275453A patent/JP5722757B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP5722757B2 (ja) | 2015-05-27 |
| JP2012107014A (ja) | 2012-06-07 |
| AU1470100A (en) | 2000-05-29 |
| US20020150628A1 (en) | 2002-10-17 |
| US20050118281A1 (en) | 2005-06-02 |
| US20020025344A1 (en) | 2002-02-28 |
| BR9915174A (pt) | 2001-11-06 |
| WO2000027390A1 (en) | 2000-05-18 |
| AU776212B2 (en) | 2004-09-02 |
| JP2002529411A (ja) | 2002-09-10 |
| US6838095B2 (en) | 2005-01-04 |
| EP1128824A1 (en) | 2001-09-05 |
| US20030147970A1 (en) | 2003-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6838095B2 (en) | Ionic silver complex | |
| RU2228177C2 (ru) | Назальная композиция и способ профилактики и лечения простуды и гриппа вирусного происхождения | |
| US20020155174A1 (en) | Acidified nitrite as an antimicrobial agent | |
| EP1531837A1 (en) | Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions | |
| JP2006526026A (ja) | 風邪及びインフルエンザ様症状の予防及び治療のためのキレート化亜鉛を含む組成物 | |
| AU3261799A (en) | Inorganic nitrite and organic acid in combination as topical antiviral composition | |
| US8513225B2 (en) | Composition and method for topical treatment of skin lesions | |
| US20110287113A1 (en) | Treatment of psoriasis | |
| US20130337042A1 (en) | Use of PVP-Iodine Liposomes for Treatment of Herpes | |
| KR20200081160A (ko) | 염화나트륨 함유 포비돈 요오드 안정 조성물 및 방법 | |
| CN105640916A (zh) | 兼具抗菌、护肤消炎作用的聚维酮碘泡腾片及其生产工艺 | |
| WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
| CN102670648A (zh) | 液态碘消毒制剂、制备方法及使用的容器 | |
| EP0000670A1 (en) | Therapeutic selenium compositions and the use thereof | |
| US20180228837A1 (en) | Stable iodine solutions with medical applications | |
| WO2007017901A2 (en) | Silver nanoparticle dispersion formulation | |
| MXPA01005900A (en) | Ionic silver complex | |
| JPH10265405A (ja) | インスリン含有の皮膚外用製剤 | |
| CN102846661B (zh) | 一种复方纳米银乳膏及其制备方法 | |
| JPS5936609A (ja) | 粘着性貼付製剤 | |
| US20220249543A1 (en) | Trona Based Therapeutic Compositions and Use and Manufacture Thereof | |
| CN110638832A (zh) | 一种纳米银利多卡因抗菌止痛贴及其制备方法 | |
| CN112352789A (zh) | 一种银氯离子共生型消毒浓缩液的制备方法 | |
| MXPA01009277A (en) | Iodine preparation compositon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |